Amicus Therapeutics- the Biopharmaceutical Power Company

The biopharmaceutical company called Amicus Therapeutics based out of Cranbury, New Jersey began with the ultimate goal of helping those with rare and orphan diseases. In their goal to helping fight against these rare diseases, they have the means to conduct safe research to help develop new methods of treatments and to even improve upon old treatments. Manned by a dedicated staff of innovative employees, who are at the forefront of developing new therapies for rare and orphan diseases (GoogleFinance).

 

Amicus Therapeutics has specialized in treating many different types of diseases, for example, Fabry Disease a mutation that causes long term damage to organ’s tissues. With the committed and passionate staff at their disposal, they have developed many treatments to combat the very same disease. At Amicus Therapeutics product development is based on their largely used Chaperone-Advanced Replacement Therapy which is a platform for the development of enzyme replacement therapies. The platform allows for safe progression from a concept to new breakthroughs in treatment for rare and orphan diseases.

 

At the Core of Amicus Therapeutics values are teamwork, passion, and fairness toward their staff and the patients they treat. The aim of their passion is being in the forefront of the newest therapies and in doing so by engaging it with ferocity and tenacious questioning and research (http://www.gcreport.com/amicus-therapeutics-announces-new-drug-application/). Armed with innovation the Amicus Therapeutics team aims to heal patients with fairly priced medicines that are broadly accessible to the public. The employees at Amicus Therapeutics believe in respecting each and every individual’s contribution, with a diversity of expertise and experiences they allow for professional and healthy work-life style. When the staff crafted those goals it had created a set of standards in which they are proud to stand by emboldening their resolve to deliver safe and effective medicines to those afflicted with rare diseases.